26.69
price down icon0.96%   -0.26
after-market After Hours: 28.02 1.33 +4.98%
loading
Oruka Therapeutics Inc stock is traded at $26.69, with a volume of 126.52K. It is down -0.96% in the last 24 hours and up +4.79% over the past month. Oruka Therapeutics Inc is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. It is to offer patients suffering from chronic skin diseases like plaque psoriasis.
See More
Previous Close:
$26.95
Open:
$26.91
24h Volume:
126.52K
Relative Volume:
2.24
Market Cap:
$934.11M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-10.94%
1M Performance:
+4.79%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
Value
$26.28
$27.27
1-Week Range:
Value
$26.28
$30.40
52-Week Range:
Value
$22.51
$31.13

Oruka Therapeutics Inc Stock (ORKA) Company Profile

Name
Name
Oruka Therapeutics Inc
Name
Phone
(720) 940-2200
Name
Address
10170 CHURCH RANCH WAY, WESTMINSTER
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
ORKA's Discussions on Twitter

Oruka Therapeutics Inc Stock (ORKA) Latest News

pulisher
Nov 04, 2024

Oruka Therapeutics to Present at Multiple November Investor Conferences - StockTitan

Nov 04, 2024
pulisher
Oct 11, 2024

Oruka stock draws buy rating at Stifel (NASDAQ:ORKA) - Seeking Alpha

Oct 11, 2024
pulisher
Oct 07, 2024

Oruka Therapeutics shares gain buy rating as H.C. Wainwright sees strong future in psoriasis treatment - Investing.com Canada

Oct 07, 2024
pulisher
Oct 04, 2024

Oruka Therapeutics Adjusts Executive Severance Agreements - TipRanks

Oct 04, 2024
pulisher
Sep 27, 2024

Oruka Therapeutics (NASDAQ:ORKA) Stock Quotes, Forecast and News Summary - Benzinga

Sep 27, 2024
pulisher
Sep 25, 2024

Oruka shares rise as TD Cowen maintains buy on drug potential - Investing.com Canada

Sep 25, 2024
pulisher
Sep 25, 2024

Oruka Therapeutics reveals promising preclinical data for psoriasis treatment - Investing.com

Sep 25, 2024
pulisher
Sep 25, 2024

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of ... - The Bakersfield Californian

Sep 25, 2024
pulisher
Sep 25, 2024

Oruka Therapeutics Announces Preclinical Data for ORKA-001 - GlobeNewswire

Sep 25, 2024
pulisher
Sep 25, 2024

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress - StockTitan

Sep 25, 2024
pulisher
Sep 24, 2024

Ordell Minerals Advances Gold Prospects with Phase 2 Drilling - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

Orkla ASA (OTCMKTS:ORKLY) Sets New 1-Year High at $9.47 - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Orgenesis announces reverse stock split to meet Nasdaq requirements By Investing.com - Investing.com Australia

Sep 24, 2024
pulisher
Sep 24, 2024

Orora (OTCMKTS:ORRYY) Shares Up 32.6% - Defense World

Sep 24, 2024
pulisher
Sep 23, 2024

Why Orgenesis (ORGS) Stock Is Down 23% Today - Benzinga

Sep 23, 2024
pulisher
Sep 23, 2024

‘Omni Loop’ takes a bit too much on its plate - Daily Trojan Online

Sep 23, 2024
pulisher
Sep 22, 2024

Private Auckland hospital doubles in size: New $3m robot, extra beds, surgical expansion - New Zealand Herald

Sep 22, 2024
pulisher
Sep 22, 2024

Organon: A Surprising Deal (NYSE:OGN) - Seeking Alpha

Sep 22, 2024
pulisher
Sep 21, 2024

‘Omni Loop’ (2024) Movie ReviewNothing New | MOVIESR.NET - Midgard Times

Sep 21, 2024
pulisher
Sep 21, 2024

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $41.25 Average PT from Analysts - Defense World

Sep 21, 2024
pulisher
Sep 20, 2024

Halozyme's ENHANZE® (HALO) Technology Empowers OCREVUS ZUNOVO™: A New Era in MS Treatment - BP Journal

Sep 20, 2024
pulisher
Sep 19, 2024

Oruka Therapeutics (NASDAQ:ORKA) Coverage Initiated at Leerink Partners - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Research Analysts Offer Predictions for Oruka Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ORKA) - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Oruka Therapeutics (NASDAQ:ORKA) Stock Rating Upgraded by Leerink Partnrs - Defense World

Sep 19, 2024
pulisher
Sep 18, 2024

Ocugen Inc [OCGN] Stock bought by Insider RAMESH KUMAR for $0.15 million - Knox Daily

Sep 18, 2024
pulisher
Sep 18, 2024

‘Omni Loop’ Review: Sci-Fi Indie Offers Some Ham-Fisted Heart - Observer

Sep 18, 2024
pulisher
Sep 18, 2024

Lifesci Capital Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA) - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

TD Cowen Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA) - Defense World

Sep 18, 2024
pulisher
Sep 17, 2024

Leerink Partners starts drug developer Oruka with 'outperform' - XM

Sep 17, 2024
pulisher
Sep 17, 2024

Oruka Therapeutics initiated with an Outperform at Leerink - TipRanks

Sep 17, 2024
pulisher
Sep 16, 2024

Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections - Benzinga

Sep 16, 2024
pulisher
Sep 16, 2024

Roche scores first, with FDA approval of Ocrevus Zunovo for MS - The Pharma Letter

Sep 16, 2024
pulisher
Sep 16, 2024

Analysts Issue Forecasts for Oruka Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ORKA) - Defense World

Sep 16, 2024
pulisher
Sep 16, 2024

FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech - Pharmaceutical Technology

Sep 16, 2024
pulisher
Sep 15, 2024

Oruka Therapeutics (NASDAQ:ORKA) Coverage Initiated at Jefferies Financial Group - Defense World

Sep 15, 2024
pulisher
Sep 13, 2024

Oruka Therapeutics Secures $200M to Advance Skin Disease Treatments - TipRanks

Sep 13, 2024
pulisher
Sep 13, 2024

FDA approves new multiple sclerosis treatment OCREVUS ZUNOVO By Investing.com - Investing.com Australia

Sep 13, 2024
pulisher
Sep 13, 2024

Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis - PR Newswire

Sep 13, 2024
pulisher
Sep 13, 2024

FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug - STAT

Sep 13, 2024
pulisher
Sep 13, 2024

Oruka to advance psoriasis programs into clinic next year - BioWorld Online

Sep 13, 2024
pulisher
Sep 12, 2024

Jefferies starts Oruka Therapeutics with buy, $40 target - Investing.com UK

Sep 12, 2024
pulisher
Sep 12, 2024

Biotech firm enters $200M agreement - The Business Journals

Sep 12, 2024
pulisher
Sep 12, 2024

Oruka Therapeutics secures $200 million in PIPE financing By Investing.com - Investing.com Canada

Sep 12, 2024
pulisher
Sep 12, 2024

Oruka Therapeutics sets clinical trial dates for skin disease drugs - Investing.com

Sep 12, 2024
pulisher
Sep 12, 2024

Oruka Therapeutics secures $200 million in PIPE financing - Investing.com

Sep 12, 2024
pulisher
Sep 12, 2024

Oruka Therapeutics Announces $200 Million Private Placement - GlobeNewswire

Sep 12, 2024
pulisher
Sep 12, 2024

Oruka Therapeutics Announces Accelerated Clinical Timelines - GlobeNewswire

Sep 12, 2024
pulisher
Sep 12, 2024

Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19 - StockTitan

Sep 12, 2024
pulisher
Sep 06, 2024

Oruka Therapeutics (NASDAQ:ORKA) Upgraded at Wedbush - Defense World

Sep 06, 2024
pulisher
Sep 05, 2024

Arca Biopharma, Oruka Therapeutics merger complete - Boulder Daily Camera

Sep 05, 2024
pulisher
Sep 05, 2024

Oruka Therapeutics (NASDAQ:ORKA) Receives New Coverage from Analysts at Wedbush - Defense World

Sep 05, 2024

Oruka Therapeutics Inc Stock (ORKA) Financials Data

There is no financial data for Oruka Therapeutics Inc (ORKA). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Oruka Therapeutics Inc Stock (ORKA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
JANUS HENDERSON GROUP PLC
10% Owner
Jul 24 '24
Buy
3.20
189,856
606,873
2,081,168
JANUS HENDERSON GROUP PLC
10% Owner
Jul 25 '24
Buy
3.05
30,227
92,292
2,111,395
JANUS HENDERSON GROUP PLC
10% Owner
Jul 03 '24
Buy
3.55
166,042
589,565
1,648,577
JANUS HENDERSON GROUP PLC
10% Owner
Jul 11 '24
Buy
3.45
94,537
326,304
1,891,312
JANUS HENDERSON GROUP PLC
10% Owner
Jul 10 '24
Buy
3.46
55,463
192,130
1,796,775
JANUS HENDERSON GROUP PLC
10% Owner
Jul 08 '24
Buy
3.46
47,492
164,190
1,724,395
JANUS HENDERSON GROUP PLC
10% Owner
Jul 05 '24
Buy
3.43
28,326
97,065
1,676,903
JANUS HENDERSON GROUP PLC
10% Owner
Jul 09 '24
Buy
3.43
16,917
58,091
1,741,312
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):